CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

19982

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 19-982

Ledêrle Laboratories
A Division of American Cyanamid Company
Attention: Maureen H. Garvey, Ph.D.
401 N. Middletown Road
Pearl River, NY 19065-1299

JUL 31 1992

Dear Dr. Garvey:

Please refer to your July 28, 1989 new drug application submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for Zebeta (bisoprolol fumarate) 5 and 10 mg Tablets.

We also acknowledge receipt of your amendments dated November 5, 11 and 19 and December 12, 13 and 20, 1991; January 30, March 13 and July 20 and 31, 1992 and your correspondence dated February 20, May 7 and July 8, 1992.

We have completed the review of this application including the submitted draft labeling and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted draft labeling. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling with a font size of 6 points or greater. Marketing the product with FPL that is not identical to this draft labeling may render the product misbranded and an unapproved new drug.

Please submit twelve copies of the FPL as soon as available. Please individually mount seven of the copies on heavy weight paper or similar material. For administrative purposes this submission should be designated "FINAL PRINTED LABELING" for approved NDA 19-982. Approval of this labeling by FDA is not required before it is used.

Should additional information relating to the safety and effectiveness of the drug become available prior to our receipt of the final printed labeling, revision of that labeling may be required.

In addition, we would appreciate your submitting copies of the introductory promotional material that you propose to use for this product. Please submit one copy to the Division of Cardio-Renal Drug Products and a second, along with a copy of the package insert, directly to:

Division of Drug Marketing, Advertising and Communications, HFD-240
5600 Fishers Lane, Room 11B06
Rockville, Maryland 20857

Please submit all proposed materials in draft or mock-up form, not final print. Also, please do not use form FD-2253 for this submission; this form is for routine use, not proposed materials.

Please submit one market package of the drug when it is available.

Please set your dissolution specifications as follows:

Apparatus Type: USP Method #2
Medium: Dearated Water, 900 mL
Speed of Rotation: 75 rpm
Sampling Time: minutes
Q Value: %

The above specification is based on data you provided on the lots used in your bioavailability/bioequivalence studies. We are aware that your stability data were generated at a higher rotation speed of 100 rpm. If subsequent stability data demonstrate that the lower speed is unacceptable, we would consider a supplement to increase the speed to 100 rpm.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact:

Ms. Zelda McDonald
Consumer Safety Officer
(301) 443-4730

Sincerely yours,

Robert Temple, M.D.
Director
Office of Drug Evaluation I
Center for Drug Evaluation and Research

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

19982

APPROVABLE LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 19-982

Lederle Laboratories
A Division of American Cyanamid Company
Attention: Maureen H. Garvey, Ph.D.
401 N. Middletown Road
Pearl River, NY 10965-1299

JUN 11 1992

Dear Dr. Garvey:

Please refer to your July 28, 1989 new drug application submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for Probeta (bisoprolol fumarate) 5 and 10 mg Tablets.

We also acknowledge receipt of your amendments dated November 22, and December 27, 1989; January 11, February 7 (two) and 13, June 18 (two), August 9 and 28, September 10, 19, 24, and 28, October 30, November 1 and 26, and December 3 and 12, 1990; January 24, February 13, March 27, July 17, and August 7, 1991 and your correspondence dated November 16, 1989 (two), January 30, February 6, May 4, July 5, and October 15 and 30, 1990; January 7 (two) and 18, May 14, June 11, July 16 and 30, September 10 and 30, and October 17 and 22 (two), 1991.

We have completed the review of this application as submitted with draft labeling. Before the application may be approved, however, it will be necessary for you to submit final printed labeling for the drug. The labeling should be identical in content to the enclosed marked-up draft. If additional information relating to the safety or effectiveness of this drug becomes available before we receive the final printed labeling, revision of that labeling may be required.

Please submit twelve copies of the printed labels and other labeling, seven of which are individually mounted on heavy weight paper or similar material.

In addition, we would appreciate your submitting copies of the introductory promotional material that you propose to use for this product. Please submit one copy to the Division of Cardio-Renal Drug Products and a second, along with a copy of the package insert, directly to:

Division of Drug Marketing, Advertising and Communication, HFD-240
5600 Fishers Lane, Rm 11B06
Rockville, Maryland 20857

Please submit all proposed materials in draft or mock-up form, not final print. Also, please do not use form FD-2253 for this submission; this form is for routine use, not proposed materials.

Within 10 days after the date of this letter, you are required to amend the application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of such action FDA may take action to withdraw the application.

The drug may not be legally marketed until you have been notified in writing that the application is approved.

Should you have any questions, please contact:

Ms. Zelda McDonald
Consumer Safety Officer
Telephone: (301) 443-4730

Sincerely yours,

6/11/92

Robert Temple, M.D.
Director
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure: Marked-up draft labeling